Efficacy and tolerability of the investigational topical cream SD-101 (6% allantoin) in patients with epidermolysis bullosa: a phase 3, randomized, double-blind, vehicle-controlled trial (ESSENCE study)

BACKGROUND: Epidermolysis bullosa (EB) is a rare genetic disorder that manifests as blistering and/or skin erosion. There is no approved treatment for EB; current standard of care consists of wound and pain management. SD-101 6% is a topical cream containing 6% allantoin that was developed for treat...

Descripción completa

Detalles Bibliográficos
Autores principales: Paller, Amy S., Browning, John, Nikolic, Milos, Bodemer, Christine, Murrell, Dedee F., Lenon, Willistine, Krusinska, Eva, Reha, Allen, Lagast, Hjalmar, Barth, Jay A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7310548/
https://www.ncbi.nlm.nih.gov/pubmed/32576219
http://dx.doi.org/10.1186/s13023-020-01419-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7310548/
https://www.ncbi.nlm.nih.gov/pubmed/32576219
http://dx.doi.org/10.1186/s13023-020-01419-3

Ejemplares similares